title: Alpha-lipoic acid inhibits peridural fibrosis following laminectomy through the inactivation of TGF-β1, PDGF, PAI-1 and IL-6 expressions.
abstract: OBJECTIVE
  The objective of this study was to investigate the antifibrotic effect of parenteral administration of alpha-lipoic acid (ALA), which has been reported to reduce fibrosis in the liver, oral mucosa, and peritoneum, in laminectomized rabbits as a potential candidate for the prevention of peridural fibrosis.
  
  
  METHODS
  Twelve adult New Zealand white male rabbits were divided into control (n=6) and ALA treatment groups (n=6). Laminectomy of the lumbar spine was performed in all animals, and ALA was administered intramuscularly in six rabbits composing the treatment group. Total RNA obtained from the paraffin-embedded tissues was analyzed for transforming growth factor-β1 (TGF-β1), plateletderived growth factor (PDGF), plasminogen activator inhibitor-1 (PAI-1) and interleukin-6 (IL-6).
  
  
  RESULTS
  mRNA investigations showed that TGF-β1, PDGF, PAI-1 and IL-6 gene expressions, which constitute strong evidence for the development of fibrosis, were significantly lower in the treatment group compared with the results obtained from the control group. According to the histological peridural grading, the ALA-treated group showed significantly less peridural fibrosis than the control group.
  
  
  CONCLUSIONS
  Intramuscular administration of ALA is a promising treatment for the prevention of peridural fibrosis in the postoperative period.
authors: Kafkas University, Faculty of Medicine, Department of Neurosurgery, Kars,Turkey.
authors: Can Hakan
authors: CH
authors: Yildirim
authors: Seyho Cem
authors: SC
authors: Yucetas
authors: Miktat
authors: M
authors: Kaya
authors: Cem
authors: C
authors: Ozic
authors: Mehmet Bulent
authors: MB
authors: Balioğlu
authors: Huseyin
authors: H
authors: Ustun
authors: Erol
authors: E
authors: Tasdemiroglu
authors: Aytac
authors: A
authors: Akbasak
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004388:Dura Mater / Q000187:drug effects; D055111:Failed Back Surgery Syndrome / Q000378:metabolism / Q000517:prevention & control; D005355:Fibrosis / Q000378:metabolism / Q000517:prevention & control*; D007273:Injections, Intramuscular; D015850:Interleukin-6 / Q000378:metabolism; D007796:Laminectomy; D008159:Lumbar Vertebrae / Q000473:pathology / Q000601:surgery; D008297:Male; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D010982:Platelet-Derived Growth Factor / Q000378:metabolism; D011183:Postoperative Complications / Q000378:metabolism / Q000517:prevention & control*; D011817:Rabbits; D008063:Thioctic Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D053773:Transforming Growth Factor beta1 / Q000378:metabolism
chemical_list: D000975:Antioxidants; D015850:Interleukin-6; D017395:Plasminogen Activator Inhibitor 1; D010982:Platelet-Derived Growth Factor; D053773:Transforming Growth Factor beta1; D008063:Thioctic Acid